MétaCan
Menu
← Back to cohort
Record W4416066815 · doi:10.1681/asn.2025983yydft

Suboptimal Use of Guideline-Directed Medical Therapy Among Patients with Newly Diagnosed CKD in the United States

2025· article· en· W4416066815 on OpenAlexaff
Lydia Yejin Lee, Adrian R. Levy, Nancy A Witkowski, Lindsay G.S. Bengtson

Bibliographic record

VenueJournal of the American Society of Nephrology · 2025
Typearticle
Languageen
FieldMedicine
TopicChronic Kidney Disease and Diabetes
Canadian institutionsDalhousie University
Fundersnot available
KeywordsMedical therapyKidney diseaseMEDLINENephrologyDialysis Therapy

Abstract

fetched live from OpenAlex

Background: With the recent expansion of the KDIGOClinical PracticeGuideline for the Evaluation and Management of Chronic Kidney Disease (CKD) in 2024 and increasing availability of CKD treatments, greater emphasis is being placed on timely utilization of guideline-directed medical therapy, including renin-angiotensin-aldosterone system inhibitors (RAASi), statins, and sodium-glucose co-transporter 2 inhibitors (SGLT2i). This study examines the use of these classes of medications in newly diagnosed adults with CKD in the United States. Methods: A retrospective study using Optum® Market Clarity™ from 2021 to 2023 was conducted. The cohort included adults with two estimated glomerular filtration rate (eGFR) measures <60ml/min/1.73m2, 3-12 months apart, followed by CKD diagnosis. The percentage of patients receiving a RAASi, statin, or SGLT2i within 90 and 365 days of CKD diagnosis and the baseline sociodemographic characteristics are presented annually from 2021-2023. Results: The cohort comprised 82,061 individuals with laboratory-confirmed diagnosis of CKD (mean age: 74 years, SD: 10). Between 2021 and 2023, annual rates of medication fills within 90 days of CKD diagnosis, remained stable for RAASi (52% to 53%), declined approximately 10% for statins (57% to 52%), and nearly doubled for SGLT2i (5% to 9%). Within 365 days, similar patterns were observed, albeit with higher overall use for each medication class relative to within 90 days (Figure 1). From 2021 to 2023, most patients receiving medical therapy had Stage 3 CKD and the average age of patients and the proportion of those insured by Medicare Advantage have generally increased (Figure 2). Conclusion: In this newly diagnosed CKD cohort, use of guideline-directed medical therapy remains low, thus suboptimal, and for statins is declining slightly. There should be an increased focus on guideline-directed medical therapy of CKD by primary care providers and specialists in nephrology, cardiology and endocrinology fostered by the development and implementation of medication-related quality measures. Additional research on the benefits of timely CKD medical therapy is warranted. Funding: Commercial Support - Boehringer Ingelheim

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.002
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.033
Threshold uncertainty score0.067

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.002
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0010.001
Science and technology studies0.0000.000
Scholarly communication0.0010.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.012
GPT teacher head0.281
Teacher spread0.269 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueJournal of the American Society of Nephrology→Same topicChronic Kidney Disease and Diabetes→French-language works237,207→